Amarin Corporation plc - American Depositary Receipt (AMRN)
NASDAQ (CM) NASDAQ (CM) Primary 
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU
AMRN jumps 27% after inking an exclusive EU licensing deal with Recordati to expand Vazkepa's reach and cut costs.
Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock?
Amarin (AMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Amarin (AMRN) Now Trades Above Golden Cross: Time to Buy?
From a technical perspective, Amarin Corporation PLC (AMRN) is looking like an interesting pick, as it just reached a key level of support. AMRN's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Here is how Amarin (AMRN) and GSK (GSK) have performed compared to their sector so far this year.
Amarin (AMRN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Amarin (AMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for June 10th
AMRN, FIX and PATH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 10, 2025.
New Strong Buy Stocks for June 10th
FIX, GHLD, AMRN, VCISY and NWFL have been added to the Zacks Rank #1 (Strong Buy) List on June 10, 2025.
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y
AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.
Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript
Amarin Corporation plc (NASDAQ:AMRN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations Aaron Berg - President and Chief Executive Officer Peter Fishman - Vice President and Global Controller Steven Ketchum - Executive Vice President, President of R&D and Chief Scientific Officer Conference Call Participants Operator Welcome to Amarin Corporation's Conference Call to discuss its First Quarter 2025 Business Update and Financial Results. I would like to turn the conference call over to Mark Marmur, Vice President, Corporate Communications and Investor Relations at Amarin.
Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript
Amarin Corporation plc (NASDAQ:AMRN ) Q4 2024 Earnings Conference Call March 12, 2025 8:00 AM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations Aaron Berg - President and Chief Executive Officer Peter Fishman - Vice President and Global Controller Steven Ketchum - Executive Vice President, President of R&D and Chief Scientific Officer Conference Call Participants Jessica Fye - JPMorgan Chase & Co. Operator Welcome to Amarin Corporation's Conference Call to discuss its Fourth Quarter and Full Year 2024 Business Update and Financial Results. I would like to turn the conference call over to Mark Marmur, Vice President, Corporate Communications and Investor Relations at Amarin.
After Plunging -19.13% in 4 Weeks, Here's Why the Trend Might Reverse for Amarin (AMRN)
Amarin (AMRN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates
AMRN's third-quarter 2024 earnings meet estimates while revenues miss the same. Vascepa's sales in the United States decline year over year.
